One of state's last life science unicorns gets 2nd shot from FDA

Intarcia Therapeutics is hoping, finally, to launch its matchstick-sized diabetes pump — two years after an FDA rejection threw the company for a loop. Type 2 diabetes affects roughly 27 million Americans.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.